In vitro studies have identified multiple mechanisms of Pt therapy resistance and preclinical and clinical studies have identified genomic (i.e. TP53 mutation) and epigenetic events which are associated with decreased tumor response [17]. This evidence concerns the gene TP53 and neoplasm.